Antibody-drug conjugates payloads: then, now and next
Drug Target Review
OCTOBER 4, 2023
Recent efforts are breathing new life into geldanamycin through the construction of a fusion protein made with an anti-HER2 scFv and an HSP90 inhibitor-binding domain (HER2 scFv-HBD), which has resulted in improved anti-cancer efficacy in HER2-positive cancers when loaded with geldanamycin derivatives. Hematol Oncol 16 , 3 (2023).
126 
Let's personalize your content